A recent investigation demonstrated that the incorporation of a peptide derived from PSMA or T cell receptor γ alternate reading frame protein (TARP) into an optimized spherical nucleic acid (SNA) vaccine markedly influenced the adaptive immune response to established prostate cancer targets in clinical settings [63]. The gene discussed is FOLH1; the disease is prostate carcinoma.